(Q38669190)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26667069%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Safety of mTOR inhibitors in adult solid organ transplantation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26667069%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

main subject

organ transplantation

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26667069%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Pedro Ventura-Aguiar

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26667069%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Josep Maria Campistol

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26667069%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

28 January 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26667069%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Safety

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26667069%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26667069%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26667069%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

303-319

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26667069%20AND%20SRC:MED&resulttype=core&format=json

Making new contacts: the mTOR network in metabolism and signalling crosstalk

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

The pros and the cons of mTOR inhibitors in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

The multifaceted role of mTORC1 in the control of lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

A Central role for mTOR in lipid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

mTOR complex 2 in adipose tissue negatively controls whole-body growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and rapamycin in a renal transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Rhabdomyolysis as a clinical manifestation of association with ciprofibrate, sirolimus, cyclosporine, and pegylated interferon-α in liver-transplanted patients: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Sirolimus is associated with new-onset diabetes in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Post-rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Proteinuria after renal transplantation affects not only graft survival but also patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Sirolimus interacts with pathways essential for podocyte integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Sirolimus damages podocytes in rats with protein overload nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Thrombotic microangiopathy after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Thrombotic microangiopathy associated with tacrolimus in lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Drug-induced thrombotic microangiopathy: a systematic review of published reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

De novo thrombotic microangiopathy after non-renal solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Immunosuppressive drugs for kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

mTOR inhibition and erythropoiesis: microcytosis or anaemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Immunobiology of human cytomegalovirus: from bench to bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Seroprevalence of cytomegalovirus infection in the United States, 1988-1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

De novo mTOR inhibitor-based immunosuppression in ABO-incompatible kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Seroepidemiology of human polyomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Case report of a kidney transplant recipient converted to everolimus due to malignancy: resolution of bronchiolitis obliterans organizing pneumonia without everolimus discontinuation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Sirolimus-associated pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers--insights from the bench side

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Radiation-induced VEGF-C expression and endothelial cell proliferation in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Pulmonary alveolar proteinosis: a rare pulmonary toxicity of sirolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Spectrum of cancer risk among US solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Acute rejection, T-cell-depleting antibodies, and cancer after transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Sirolimus use and cancer incidence among US kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Skin cancers after organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Sirolimus and secondary skin-cancer prevention in kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

The utilization of sirolimus and the impact on wound-healing complications in obese kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Everolimus and long-term outcomes in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

mTOR inhibitors and unilateral edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Strategies for the management of adverse events associated with mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Mammalian target of rapamycin inhibitor-associated stomatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

mTOR inhibitor-associated dermatologic and mucosal problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2016.1132698